Funded Projects

Browse wide-ranging research at the frontiers of neuroscience supported by Wu Tsai Neurosciences Institute grants, awards, and training fellowships.

Wu Tsai Neurosciences Institute
Neuroscience:Translate Award
2024
Small molecule ion channel modulator to treat acute episodes of peripheral vertigo

This team is developing a small molecule that targets a voltage-gated ion channel within the inner ear for the symptomatic relief of peripheral vertigo attacks. They will use their Neuroscience:Translate award to further develop this molecule to restore normal function and improve activities of daily living for patients experiencing peripheral vertigo.

Wu Tsai Neurosciences Institute
Neuroscience:Translate Award
2024
Creating a pharmacologic stroke recovery therapy

This team has identified a promising protein-based therapeutic to improve stroke recovery.  The team will use the Neuroscience:Translate award to identify key components of this protein to maximize its therapeutic potential for stroke treatments.

Wu Tsai Neurosciences Institute
Neuroscience:Translate Award
2024
Clinical translation of a new PET radiotracer for mapping innate immune activation in multiple sclerosis and other neurodegenerative diseases

This team recently identified a selective biomarker of inflammation-promoting immune cells in the central nervous system. They will use their Neuroscience:Translate award to develop non-invasive molecular imaging strategies to distinguish between harmful (pro-inflammatory) and helpful (anti-inflammatory) immune cells in patients with Multiple sclerosis (MS).

Wu Tsai Neurosciences Institute
Neuroscience:Translate Award
2024
Assessing the feasibility of an autologous cell/gel therapy for spinal cord injury

This team has developed a new therapy for patients with spinal cord injury, involving injection into the spinal cord of patient-derived stem cells within an engineered protective gel. They will use their Neuroscience:Translate award to further test and develop this novel therapy in preparation for first-in-human clinical trials. 

Wu Tsai Neurosciences Institute
Neuroscience:Translate Award
2024
Targeting mitochondria in glioblastoma

This team recently discovered that a small molecule they had originally developed to treat Parkinson’s disease can also reduce the volume of glioblastoma tumors – the most common form of aggressive brain tumor — by targeting the mitochondrial protein Miro1. They will use their Neuroscience:Translate award to study the mechanisms of the compound’s anti-tumor action and prepare to apply for investigational-new-drug status to move this discovery toward the clinic.